Research Progress and Application of Bioorthogonal Reactions in Biomolecular Analysis and Disease Diagnosis

Punicalagin alleviates the hyperproliferation of keratinocytes in psoriasis through inhibiting SKP2 expression

Psoriasis is a chronic inflammatory skin disorder characterized by abnormal keratinocytes proliferation and multiple immune cells infiltration in the dermis and epidermis. Although most psoriasis-related researches have been concentrated on the interleukin-23 (IL-23)/interleukin-17 (IL-17) axis, new data suggest that keratinocytes also play a pivotal role in psoriasis. Previously, we found that punicalagin (PUN), a bioactive ellagitannin extracted from Pericarpium Granati (the pericarpium of Punica granatum L.), exerts a therapeutic effect on psoriasis. However, the underlying mechanism, especially its potential modulatory effect on keratinocytes, remains obscure. Our study aims to reveal the potential regulatory effect and its underlying cellular mechanism of PUN on the hyperproliferation of keratinocytes. We used tumor necrosis factor α (TNF-α), IL-17A and interleukin-6 (IL-6) to induce abnormal proliferation of HaCaT cells (Human Keratinocytes Cells) in vitro. Then, we evaluated the effects of PUN through MTT assay, EdU staining and cell cycle detection. Finally, we explored the underlying cellular mechanisms of PUN via RNA-sequencing, WB in vitro and in vivo. Here, we found that PUN can directly and dose-dependently decrease TNF-α, IL-17A and IL-6-induced abnormal proliferation of HaCaT cells in vitro. Mechanically, PUN suppresses the hyperproliferation of keratinocytes through repressing S-phase kinase-associated protein 2 (SKP2) expression in vitro and in vivo. Moreover, overexpression of SKP2 can partly abolish PUN-mediated inhibition of aberrantly proliferative keratinocytes. These results illustrate that PUN can reduce the severity of psoriasis through directly repressing SKP2-mediated abnormal proliferation of keratinocytes, which gives new insight into the therapeutic mechanism of PUN on psoriasis. Moreover, these findings imply that PUN might be a promising drug candidate for the treatment of psoriasis.

Design, synthesis and bioactivity evaluation of self-assembled PROTACs based on multi-target kinase inhibitors

Proteolysis targeting chimera (PROTAC) is a heterobifunctional molecule with enormous potential for its ability to overcome the limitations of traditional inhibitors. However, its inherent disadvantages have been increasingly revealed, such as poor cell permeability caused by large molecule weight. Herein, to overcome the inherent shortcomings, intracellular self-assembly was proposed based on bioorthogonal reaction and molecular fragments, affording a novel type of self-assembled PROTACs. Two types of precursors incorporated with tetrazine and norbornene as bioorthogonal groups were designed and synthesized, and they could subsequently be conjugated in cells to generate novel PROTACs. Fortunately, ultrafast HRMS and HPLC assays indicated that self-assembled PROTACs driven by the bio-orthogonal reaction were detected in living U87 cells. Biological evaluation suggested that the precursor molecule LN-1 could degrade PDGFR-β protein in a concentration-dependent manner, while cancer cells were co-treated with another precursor molecule, TzB. Our findings verified the feasibility of a self-assembly strategy in future development of novel PROTACs.

Fluorogenic Protein Labeling by Generation of Fluorescent Quinoliziniums Using [Cp*RhCl2]2

Fluorogenic labeling has received considerable attention as a result of the high demand in chemical biology and synthetic biology applications. Herein, we develop a new strategy for fluorescent turn-on ligation targeting alkyne- and quinoline-linked peptides and proteins (λ_em of 515 nm and up to Φ_F of 0.20) using the [Cp*RhCl₂]₂ catalyst. The good conversion, high flexibility, broad utility, ease of use, and mild reaction conditions are great advantages to extend the rhodium-mediated turn-on fluorogenic bioconjugation for further applications.

Current Probes for Imaging Carbonylation in Cellular Systems and Their Relevance to Progression of Diseases

Oxidative stress resulted from reactive oxygen or nitrogen species in biological systems has a significant role in the diagnosis/progression of several human diseases. Human diseases associated with oxidative stress include Alzheimer's disease, chronic lung disease, chronic renal failure, cancer, diabetes, and fibrosis. In oxidative stress conditions, carbonylation process can be described as one of the most common modifications in biomolecules that takes place in the presence of carbonyl (C = O) groups which are introduced into molecules by direct metal-catalyzed oxidation of certain amino acids or indirectly by reaction with the oxidation of lipids and sugars. At a molecular cellular level, carbonylation can cause some defective biological consequences or chemical transformations in cells. During this process, specifically, carbonylated proteins can be accumulated in cells and trigger to develop some diseases in human body. The role of the accumulation of carbonylated proteins in the progression of several diseases has also been reported in the literature, such as neurodegenerative diseases, diabetes, obesity, aging, and cancer. Early detection of carbonylation process is, therefore, very critical to monitor these diseases at an early stage. Finding a suitable biomarker or probe is very challenging due to the need for multiple criteria: high fluorescence efficiency, stability, toxicity, and permeability. If they are designed with a good strategy, these probes are highly effective in cell biology applications and they can be used as good diagnostic tools for monitoring oxidative stress-induced carbonylation in relevant diseases. This review highlights the design and use of recent fluorescent probes for visualization of carbonylation in cellular systems and the relationship between oxidative stress and carbonyl species for causing long-term disease complications.